• Spyre Therapeutics Chief Medical Officer Sheldon Sloan exercised stock options for 8,333 shares at USD 27.46 on June 3.
• Sloan sold 8,333 shares the same day at USD 75, ending with 0 shares owned directly.
• Sloan reported 313,334 stock options beneficially owned following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000078), on June 03, 2026, and is solely responsible for the information contained therein.